Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (DOP2015000009) ANTAGONISTAS DEL RECEPTOR DE 5-HT3

Office : Dominican Republic
Application Number: 2015000009 Application Date: 13.01.2015
Publication Number: P2015000009 Publication Date: 15.03.2015
Publication Kind : A
Prior PCT appl.: Application Number:PCTUS2013050746 ; Publication Number:WO2014014951 Click to see the data
IPC:
C07D 401/04
C07D 401/12
C07D 401/14
C07D 403/04
C07D 451/12
C07D 471/02
C07D 487/14
C07D 498/08
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
451
Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
02
containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane; Cyclic acetals thereof
04
with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring system
06
Oxygen atoms
12
acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
12
in which the condensed system contains three hetero rings
14
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
498
Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
in which the condensed system contains two hetero rings
08
Bridged systems
CPC:
C07D 498/08
A61K 31/19
A61K 31/5386
C07C 53/18
C07C 53/40
C07D 221/22
C07D 451/12
C07D 453/02
C07D 471/04
C07D 471/08
C07D 519/00
Applicants: TAKEDA PHARMACEUTICAL COMPANY LIMITED,
Inventors: STEPHEN HITCHCOCK
HOLGER MONENSCHEIN
HOLLY REICHARD
HUIKAI SUN
SHOTA KIKUCHI
TODD MACKLIN
MARIA HOPKINS
Agents: TANIA MIGUELINA CASTILLO BAEZ
Priority Data: 61/672,709 17.07.2012 US
61/708,521 01.10.2012 US
Title: (ES) ANTAGONISTAS DEL RECEPTOR DE 5-HT3
Abstract:
(ES) La presente invención proporciona antagonistas del receptor de 5–HT3 de la Fórmula (I): que son útiles para el tratamiento de enfermedades tratables mediante la inhibición del receptor de 5–HT3 tales como émesis, dolor, adicción a las drogas, trastornos neurodegenerativos y psiquiátricos, y trastornos GI. También se proporcionan composiciones farmacéuticas que contienen dichos compuestos y procesos para la preparación de dichos compuestos.
Also published as:
CA2879115IL236702EP2875011EA201590228SG11201500302UCN104768943
JP2015522618NZ704814AU2013290375BR112015001028ID2016/04647MYPI 2015000110
PH1/2015/500085VN42301IN957/DELNP/2015ES2659758EP3312169TH180869
TN2015000018WO/2014/014951